SAN LUIS OBISPO, California – November 1, 2011 – FzioMed, Inc. (www.fziomed.com) announced that they have reached the 250,000 units sold mark. Oxiplex® is approved outside of the United States in over 70 countries worldwide under the brand names Oxiplex®, Oxiplex®/SP and MediShield™.
Oxiplex is an absorbable gel that is applied to spinal nerve roots during lumbar laminectomy, laminotomy and discectomy procedures. Oxiplex creates a temporary, protective barrier against the damaging effects of excessive fibrosis, inflammation and other irritants that can lead to recurrent postoperative pain. Oxiplex has been shown to improve spine surgery outcomes by significantly reducing postoperative leg pain, back pain and neurological symptoms.
“This significant milestone is a tribute to our employees who strive tirelessly to provide surgeons worldwide with cost effective solutions to unmet medical needs. While we are pleased with the worldwide adoption of Oxiplex, we are hopeful that an extensive database of US studies will ultimately lead to US approval so that US patients can benefit from this technology.” said John Krelle, FzioMed President and Chief Executive Officer.
FzioMed is a privately held medical device company developing and commercializing absorbable, surgical biomaterials based on the company’s patented science. FzioMed’s polymer technology has uses in a variety of surgical specialties including orthopedics, spine, gynecology, aesthetics and general surgery.
FzioMed® and Oxiplex® are registered trademarks of FzioMed, Inc.